| Literature DB >> 22140272 |
Marlene D Dalgaard1, Nils Weinhold, Daniel Edsgärd, Jeremy D Silver, Tune H Pers, John E Nielsen, Niels Jørgensen, Anders Juul, Thomas A Gerds, Aleksander Giwercman, Yvonne L Giwercman, Gabriella Cohn-Cedermark, Helena E Virtanen, Jorma Toppari, Gedske Daugaard, Thomas S Jensen, Søren Brunak, Ewa Rajpert-De Meyts, Niels E Skakkebæk, Henrik Leffers, Ramneek Gupta.
Abstract
BACKGROUND: Testicular dysgenesis syndrome (TDS) is a common disease that links testicular germ cell cancer, cryptorchidism and some cases of hypospadias and male infertility with impaired development of the testis. The incidence of these disorders has increased over the last few decades, and testicular cancer now affects 1% of the Danish and Norwegian male population.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22140272 PMCID: PMC3284313 DOI: 10.1136/jmedgenet-2011-100174
Source DB: PubMed Journal: J Med Genet ISSN: 0022-2593 Impact factor: 6.318
Constitution of discovery and replication cohorts
| Phenotype | Discovery cohort | Replication cohort |
| Controls | 439 | 235 |
| Infertile | 107 | 0 |
| TGCC | 212 | 333 |
| Hypospadias | 31 | 0 |
| Cryptorchidism | 138 | 103 |
TGCC, testicular germ cell cancer.
Figure 1Manhattan plots showing the association between all single-nucleotide polymorphisms and (A) testicular dysgenesis syndrome and (B) the subset of cases of testicular germ cell cancer.
Markers and genes with a possible association with the testicular dysgenesis syndrome (TDS) phenotype
| Gene | Marker | Selection method | Phase | Risk allele | Control RAF | OR (95% CI) | punadj | padj | Optimal genetic model | |
| Per allele | Optimal genetic model | |||||||||
| rs1352947 | TGCC | Discovery | T | 0.81 | 1.56 (1.19 to 2.05) | 1.52 (1.18 to 1.97) | 3.1×10−3 | 1 | Additive | |
| C/T | Replication | 0.82 | 2.11 (1.48 to 3.03) | 1.93 (1.39 to 2.69) | 8.5×10−5 | 2.0×10−3 | ||||
| rs12082710 | ISB | Discovery | T | 0.58 | 1.35 (1.10 to 1.65) | 1.77 (1.33 to 2.36) | 2.4×10−4 | 1 | Recessive | |
| T/C | Replication | 0.59 | 1.27 (0.99 to 1.63) | 1.52 (1.08 to 2.15) | 1.6×10−2 | 3.8×10−1 | ||||
| rs388286 | Pathway | Discovery | C | 0.47 | 1.34 (1.10 to 1.63) | 1.36 (1.11 to 1.67) | 2.3×10−3 | 1 | Additive | |
| C/T | Replication | 0.47 | 1.29 (1.01 to 1.66) | 1.28 (1.01 to 1.62) | 4.1×10−2 | 9.9×10−1 | ||||
| rs17198432 | TDS | Discovery | A | 0.07 | 2.31 (1.66 to 3.26) | 2.58 (1.82 to 3.70) | 4.7×10−8 | 2.2×10−2 | Dominant | |
| C/A | Replication | 0.11 | 0.96 (1.43 to 0.64) | 0.97 (0.64 to 1.48) | 8.7×10−1 | 1 | ||||
The marker with the lowest p value in the discovery cohort, among the markers tagging a gene, is presented.
Four different approaches were used for the selection of markers: TDS, single-marker genome-wide association study (GWAS) on all TDS sub-phenotypes; TGCC, single-marker GWAS on the testicular germ cell cancer (TGCC) subset of cases; Pathway, aggregated effect in pathways; ISB, integrative systems biology by combing evidence of association from several data types.
Risk allele frequency.
The genetic model with strongest association among the models tested by the MAX test (selected on discovery cohort).
Figure 2Integration of genome-wide association study (GWAS) data with heterogeneous data types. The rationale behind the method is to prioritise genes if several data types show mildly pronounced associations with the phenotype, thereby identifying genes that would not have been found with GWAS analysis alone. TGFBR3, which was selected by this method and whose single-nucleotide polymorphism markers were further validated, is shown in red. The position of TGFBR3 is marked by red circles in the distributions of p values, and by red squares in the ranking of each data type layer. Three data types were used: (1) single-marker GWAS results of this study (grey); (2) targeted mutations from the Mouse Genome Informatics (MGI) database, filtered for testicular dysgenesis syndrome phenotypes, and ranked by their enrichment in protein–protein complexes (pink); (3) differential expression in the fetal testis of mouse and human (green). (A) A distribution of the p values of all human genes is shown for each of the data types. The p value ranges from 0 to 1, with 0 at the top. The p value associated with each gene is converted into a rank, such that each human gene is assigned a rank. The vertical line to the right of each distribution represents the ranking of all genes, where the top corresponds to rank 1. (B) The gene ranks of each individual data type are combined to a final meta-rank of each gene. As an example, TGFBR3 had the ranks 238, 42 and 408 among all human genes in the three data types: GWAS, targeted mutations with protein–protein interaction enrichment, and differential expression in the developing testis, respectively. After combination of these data type-specific ranks, TGFBR3 was ranked 3rd among all genes. PPI, protein-protein interaction.
Figure 3Regional association plots and linkage disequilibrium structure. The −log10 of the p values for the association of discovery markers are shown, and the markers are coloured in a white to red scale according to the strength of the pairwise linkage disequilibrium (r2) to the most significant discovery marker at each locus. The blue marker represents the association in the replication stage. Light blue peaks indicate recombination rates from the CEU HapMap population. r2-based linkage disequilibrium structures from the genome-wide association study data are displayed at the bottom. (A) The strongest association in the discovery stage was found at 2q31.1, close to the cluster of HOXD genes. (B) The most significant markers in the replication stage were found at the KITLG region. The genes TGFBR3 (C) and PBM7 (D) had single-nucleotide polymorphisms with mild association in the discovery stage, but were top-ranked by the integrative data analysis, and were further validated in the replication stage.
Associations with TDS and its sub-phenotypes, TGCC, cryptorchidism, hypospadias and infertility for the top markers in the discovery stage and for replicated markers
| Gene | Marker | Phase | Risk allele | OR (95% CI) | ||||
| TDS | TGCC | Cryptorchidism | Hypospadias | Infertility | ||||
| rs1352947 | Discovery | T | 1.56 (1.18 to 1.97) | 2.74 (1.82 to 4.26) | 1.08 (0.77 to 1.55) | 1.00 (0.52 to 2.11) | 1.26 (0.86 to 1.90) | |
| Replication | 1.93 (1.39 to 2.69) | 2.23 (1.55 to 3.28) | 1.38 (0.89 to 2.24) | na | na | |||
| rs12082710 | Discovery | T | 1.77 (1.33 to 2.36) | 1.55 (1.07 to 2.23) | 1.62 (1.07 to 2.44) | 2.04 (0.90 to 4.56) | 2.38 (1.54 to 3.70) | |
| Replication | 1.52 (1.08 to 2.15) | 1.49 (1.04 to 2.14) | 1.64 (0.99 to 2.71) | na | na | |||
| rs388286 | Discovery | C | 1.36 (1.11 to 1.67) | 1.38 (1.06 to 1.79) | 1.49 (1.11 to 2.01) | 1.24 (0.70 to 2.22) | 1.21 (0.89 to 1.66) | |
| Replication | 1.28 (1.01 to 1.62) | 1.37 (1.06 to 1.78) | 1.09 (0.78 to 1.52) | na | na | |||
| rs17198432 | Discovery | A | 2.58 (1.82 to 3.70) | 2.85 (1.86 to 4.38) | 2.9 (1.81 to 4.63) | 2.83 (1.11 to 6.64) | 1.76 (1.01 to 3.01) | |
| Replication | 0.97 (0.64 to 1.48) | 0.96 (0.61 to 1.50) | 1.00 (0.52 to 1.83) | na | na | |||
na, these phenotypes were not assessed in the replication stage.
TGCC, testicular germ cell cancer; TDS, testicular dysgenesis syndrome.
Figure 4Localisation of transforming growth factor β receptor type III (TGFBR3) protein in normal fetal testis (A), adult testis with complete spermatogenesis (B), and dysgenetic adult testis with carcinoma in situ and Leydig cell hyperplasia (C). Leydig cells are marked by arrowheads (A, B, C), gonocytes (A) and CIS cells (C) by large arrows and peritubular cells by small arrows (B & C). Inserts (lower right) are without primary antibody. Bars indicate 100 μm. TGFBR3 is seen to be expressed in Leydig and peritubular cells.